With a record number of prescription drugs scheduled to go off-patent, makers of branded pharmaceuticals are "erecting barriers" to block generic competition, the trade group that represents pharmacy benefit managers said yesterday. The Pharmaceutical Care Management Association argues that the delaying tactics could cost Medicare up to $13 billion for one group of commonly prescribed drugs for seniors. The Washington Post examines the legislative and business strategies being used by all sides in the dispute. Article